Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?
Shigefuku R, Takahashi H, Kobayashi M, Ikeda H, Matsunaga K, Okuse C, Matsumoto N, Maeyama S, Sase S, Suzuki M, Itoh F. Shigefuku R, et al. Among authors: matsunaga k. J Gastroenterol. 2012 Nov;47(11):1238-47. doi: 10.1007/s00535-012-0581-4. Epub 2012 May 11. J Gastroenterol. 2012. PMID: 22576023 Clinical Trial.
Xenon computed tomography can evaluate the improvement of hepatic hemodynamics before and after endoscopic injection sclerotherapy.
Takahashi H, Suzuki M, Shigefuku R, Okano M, Hiraishi T, Takagi R, Noguchi Y, Hattori N, Hatsugai M, Nakahara K, Okamoto M, Kobayashi M, Ikeda H, Fukuda Y, Nagase Y, Ishii T, Matsunaga K, Matsumoto N, Okuse C, Sase S, Itoh F. Takahashi H, et al. Among authors: matsunaga k. J Gastroenterol. 2013 Dec;48(12):1353-61. doi: 10.1007/s00535-013-0756-7. Epub 2013 Feb 9. J Gastroenterol. 2013. PMID: 23397117
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W. Takada J, et al. Among authors: matsunaga k. BMC Res Notes. 2015 Oct 26;8:609. doi: 10.1186/s13104-015-1565-2. BMC Res Notes. 2015. PMID: 26502722 Free PMC article.
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S. Fukushima T, et al. Among authors: matsunaga k. JGH Open. 2021 Dec 17;6(1):29-35. doi: 10.1002/jgh3.12691. eCollection 2022 Jan. JGH Open. 2021. PMID: 35071785 Free PMC article.
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M. Kobayashi S, et al. Among authors: matsunaga k. BMC Cancer. 2022 May 7;22(1):517. doi: 10.1186/s12885-022-09625-x. BMC Cancer. 2022. PMID: 35525913 Free PMC article.
The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Miyake S, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: matsunaga k. J Hepatol. 2008 May;48(5):736-42. doi: 10.1016/j.jhep.2007.12.025. Epub 2008 Feb 26. J Hepatol. 2008. PMID: 18329125
Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study.
Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N. Yasui Y, et al. Among authors: matsunaga k. Oncology. 2014;86(1):53-62. doi: 10.1159/000356643. Epub 2014 Jan 8. Oncology. 2014. PMID: 24401597
1,396 results